Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec:80:105076.
doi: 10.1016/j.msard.2023.105076. Epub 2023 Oct 13.

Utilization of FDA approved treatments for neuromyelitis optica spectrum disorder in clinical practice: A survey study of academic neuroimmunologists

Jesse M Thon  1 , Robert Sharkus  2 , Richa Thakkar  2 , Krystal Hunter  3 , James E Siegler  1 , Olga R Thon  4
Affiliations

Utilization of FDA approved treatments for neuromyelitis optica spectrum disorder in clinical practice: A survey study of academic neuroimmunologists

Jesse M Thon et al. Mult Scler Relat Disord. 2023 Dec.

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune condition for which three treatments have been approved since 2019: eculizumab, inebilizumab, and satralizumab. We conducted a survey of U.S. academic neuroimmunologists to assess adoption of these therapies and barriers to use. Thirty-three neuroimmunologists from 18 states completed the survey. Nearly all (88 %) reported using the novel NMOSD treatments (NNTs). They uncommonly switched clinically stable patients to NNTs (69 % switched none, 22 % switched 1-25 % of their patients). For newly diagnosed patients, NNT initiation rates varied. Following relapse, respondents were dichotomized, either switching 75-100 % of patients (60 %) or 0-25 % (40 %). Insurance and cost-related barriers were common.

Keywords: Eculizumab; Inebilizumab; NMOSD; Neuromyelitis optica spectrum disorders; Satralizumab.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Olga Thon has received financial compensation for her participation in advisory boards and speakers’ bureaus from Horizon Therapeutics. None of the other authors have disclosures.

LinkOut - more resources